JP2012513209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012513209A5 JP2012513209A5 JP2011542856A JP2011542856A JP2012513209A5 JP 2012513209 A5 JP2012513209 A5 JP 2012513209A5 JP 2011542856 A JP2011542856 A JP 2011542856A JP 2011542856 A JP2011542856 A JP 2011542856A JP 2012513209 A5 JP2012513209 A5 JP 2012513209A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- adenoviral vector
- subject
- use according
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 230000000174 oncolytic effect Effects 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 210000000234 capsid Anatomy 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000005890 Neuroma Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 201000000052 gastrinoma Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010004272 Benign hydatidiform mole Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010067807 Gingival cancer Diseases 0.000 claims description 2
- 206010018404 Glucagonoma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000006937 Hydatidiform mole Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims description 2
- 206010062038 Lip neoplasm Diseases 0.000 claims description 2
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000000035 Osteochondroma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010036832 Prolactinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 206010041329 Somatostatinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 206010043515 Throat cancer Diseases 0.000 claims description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000006842 Tonsillar Neoplasms Diseases 0.000 claims description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 2
- 206010046392 Ureteric cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 210000000750 endocrine system Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 claims description 2
- 201000010235 heart cancer Diseases 0.000 claims description 2
- 208000024348 heart neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 206010022498 insulinoma Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000006721 lip cancer Diseases 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 208000022006 malignant tumor of meninges Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- 201000001219 parotid gland cancer Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 201000002511 pituitary cancer Diseases 0.000 claims description 2
- 201000003437 pleural cancer Diseases 0.000 claims description 2
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 208000029387 trophoblastic neoplasm Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- 208000035404 Autolysis Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 1
- 206010057248 Cell death Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 238000013459 approach Methods 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000028043 self proteolysis Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
- 230000037361 pathway Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010044002 Tonsil cancer Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20080671A FI20080671A0 (fi) | 2008-12-22 | 2008-12-22 | Onkolyyttiset virukset |
| FI20080671 | 2008-12-22 | ||
| FI20095466A FI121508B (fi) | 2008-12-22 | 2009-04-27 | Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä |
| FI20095466 | 2009-04-27 | ||
| US58597109A | 2009-09-29 | 2009-09-29 | |
| US12/585,971 | 2009-09-29 | ||
| PCT/FI2009/051025 WO2010072900A1 (en) | 2008-12-22 | 2009-12-21 | Oncolytic adenoviral vectors and methods and uses related thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156226A Division JP6280084B2 (ja) | 2008-12-22 | 2015-08-06 | 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012513209A JP2012513209A (ja) | 2012-06-14 |
| JP2012513209A5 true JP2012513209A5 (cg-RX-API-DMAC7.html) | 2014-11-27 |
Family
ID=44502296
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542856A Pending JP2012513209A (ja) | 2008-12-22 | 2009-12-21 | 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 |
| JP2015156226A Expired - Fee Related JP6280084B2 (ja) | 2008-12-22 | 2015-08-06 | 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156226A Expired - Fee Related JP6280084B2 (ja) | 2008-12-22 | 2015-08-06 | 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 |
Country Status (20)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102858959B (zh) | 2009-12-10 | 2016-02-24 | 渥太华医院研究院 | 溶瘤弹状病毒 |
| CA2812093A1 (en) * | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| BR112013006669A2 (pt) * | 2010-09-24 | 2019-09-24 | Oncos Therapeutics Oy | vetores adenovirais oncolíticos e métodos e usos relacionados aos mesmos |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US10238698B2 (en) | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| RU2684211C2 (ru) | 2013-02-21 | 2019-04-04 | Тёрнстоун Лимитед Партнершип | Композиция вакцины |
| KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
| CA2909432C (en) * | 2013-04-18 | 2025-11-18 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| US12421502B2 (en) | 2013-04-18 | 2025-09-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| ES2987442T3 (es) * | 2015-05-04 | 2024-11-14 | Theriva Biologics S L | Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer |
| FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| KR20180112024A (ko) | 2016-02-23 | 2018-10-11 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3426271B1 (en) | 2016-03-10 | 2025-08-27 | CG Oncology, Inc. | Methods of treating solid tumors by combination therapy |
| ES2845690T3 (es) | 2016-09-12 | 2021-07-27 | Targovax Oy | Combinación de adenovirus e inhibidores de punto de control para el tratamiento del cáncer |
| EP3534923A4 (en) * | 2016-11-01 | 2020-05-27 | DNAtrix, Inc. | COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| KR20190104051A (ko) * | 2017-01-06 | 2019-09-05 | 스타빌리테크 바이오파마 리미티드 | 바이러스 |
| AU2018251987B2 (en) | 2017-04-14 | 2024-11-28 | Cg Oncology, Inc. | Methods of treating bladder cancer |
| NZ758626A (en) | 2017-04-21 | 2023-09-29 | Baylor College Medicine | Oncolytic virotherapy and immunotherapy |
| AU2018273963B2 (en) | 2017-05-25 | 2023-07-20 | University Of Central Florida Research Foundation, Inc. | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells |
| US11896635B2 (en) | 2017-11-08 | 2024-02-13 | Kagoshima University | Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| AU2019251356B2 (en) | 2018-04-09 | 2025-06-12 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
| EP3725323A1 (en) | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
| EP3725888A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase |
| EP3725322A1 (en) | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing granzyme and perforin |
| US20240293487A1 (en) * | 2020-03-25 | 2024-09-05 | Jin-Woo Choi | Immunoevasive anti-tumor adenovirus |
| CN111909962A (zh) * | 2020-07-23 | 2020-11-10 | 药鼎(北京)国际细胞医学技术有限公司 | 一种治疗肝癌的病毒构建体及其用途和构建方法 |
| CN118853767A (zh) * | 2024-08-22 | 2024-10-29 | 华中科技大学同济医学院附属同济医院 | 一种新型溶瘤腺病毒载体及其构建方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002538770A (ja) * | 1998-11-10 | 2002-11-19 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ウイルスベクターとその製造及び投与の方法 |
| ATE291633T1 (de) * | 1999-06-01 | 2005-04-15 | Univ Washington | Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration |
| EP1228234A2 (en) * | 2000-03-14 | 2002-08-07 | Neurologix, Inc. | Production of chimeric capsid vectors |
| WO2005030261A1 (en) * | 2003-08-28 | 2005-04-07 | Cell Genesys, Inc. | Oncolytic adenoviral vectors encoding gm-csf |
| ES2276623B1 (es) * | 2005-12-12 | 2008-06-01 | Proyecto De Biomedicina Cima, S.L | Nuevos adenovirus recombinantes de replicacion condicionada (crad). |
| WO2007103825A2 (en) * | 2006-03-02 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Combination therapy with oncolytic adenovirus |
-
2009
- 2009-12-21 WO PCT/FI2009/051025 patent/WO2010072900A1/en not_active Ceased
- 2009-12-21 HU HUE09796016A patent/HUE031689T2/en unknown
- 2009-12-21 SI SI200931586A patent/SI2379586T1/sl unknown
- 2009-12-21 ES ES09796016.5T patent/ES2612889T3/es active Active
- 2009-12-21 PL PL09796016T patent/PL2379586T3/pl unknown
- 2009-12-21 EP EP09796016.5A patent/EP2379586B1/en active Active
- 2009-12-21 HR HRP20170165TT patent/HRP20170165T1/hr unknown
- 2009-12-21 JP JP2011542856A patent/JP2012513209A/ja active Pending
- 2009-12-21 CN CN200980151762.9A patent/CN102264760B/zh not_active Expired - Fee Related
- 2009-12-21 BR BRPI0924123A patent/BRPI0924123B8/pt not_active IP Right Cessation
- 2009-12-21 SG SG2011046109A patent/SG173432A1/en unknown
- 2009-12-21 CA CA2748180A patent/CA2748180C/en active Active
- 2009-12-21 KR KR1020117016272A patent/KR101761094B1/ko not_active Expired - Fee Related
- 2009-12-21 DK DK09796016.5T patent/DK2379586T3/en active
- 2009-12-21 AU AU2009332883A patent/AU2009332883B2/en not_active Ceased
- 2009-12-21 RU RU2011130511/10A patent/RU2520823C2/ru active
- 2009-12-21 LT LTEP09796016.5T patent/LT2379586T/lt unknown
- 2009-12-21 PT PT97960165T patent/PT2379586T/pt unknown
-
2011
- 2011-06-07 ZA ZA2011/04224A patent/ZA201104224B/en unknown
-
2015
- 2015-08-06 JP JP2015156226A patent/JP6280084B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-27 CY CY20171100126T patent/CY1120039T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012513209A5 (cg-RX-API-DMAC7.html) | ||
| JP5075839B2 (ja) | 癌の処置のための腫瘍崩壊性アデノウイルス | |
| Niemann et al. | Oncolytic viruses: adenoviruses | |
| Savontaus et al. | Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells | |
| RU2011130511A (ru) | Аденовирусные векторы и способы их применения, связанные с ними | |
| JP6170999B2 (ja) | アデノウイルスおよび化学二量体を用いる選択細胞の標的化 | |
| FI3768305T3 (fi) | Modifioituja onkolyyttisiä adenoviruksia | |
| FI3768830T3 (fi) | Syöpäterapia | |
| JP2012516682A5 (cg-RX-API-DMAC7.html) | ||
| RU2013118724A (ru) | Онколитические аденовирусные векторы и связанные с ними способы и применения | |
| Marino et al. | Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes | |
| RU2011136280A (ru) | HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ | |
| Lopez et al. | Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses | |
| Yokoda et al. | Oncolytic virotherapy in upper gastrointestinal tract cancers | |
| Lucas et al. | Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer | |
| Tomita et al. | Antibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration | |
| Sato-Dahlman et al. | The Development of Oncolytic Adenovirus Therapy in the Past and Future-For the Case of Pancreatic Cancer | |
| O’Bryan et al. | CXCL12 retargeting of an oncolytic adenovirus vector to the chemokine CXCR4 and CXCR7 receptors in breast cancer | |
| JPWO2019158914A5 (cg-RX-API-DMAC7.html) | ||
| Tanaka et al. | Cancer-targeting gene therapy using tropism-modified adenovirus | |
| Anwar et al. | Ixovex-1, a novel oncolytic E1B-mutated adenovirus | |
| Logunov et al. | Identification of HI-like loop in CELO adenovirus fiber for incorporation of receptor binding motifs | |
| Yamamoto | Conditionally replicative adenovirus for gastrointestinal cancers | |
| CN102108356B (zh) | 新颖启动子及包含其之病毒载体 | |
| CN101880688B (zh) | 一种使复制缺陷型腺病毒选择性复制的方法和用途 |